(Toronto, July 10, 2026) JMIR Publications released a feature News and Perspectives story on technological advances in oncology. Authored by JMIR Correspondent Benedette Cuffari, “ AI-Designed Radiopharmaceuticals: How Machine Learning Is Redefining Precision Cancer Therapy ” reports on the integration of deep learning and generative AI in radiopharmaceutical medicine, its impact on accelerating drug design, and how personalized dosimetry can improve patient outcomes.
AI-Powered Drug Discovery
While radiopharmaceutical therapy is highly effective for some types of cancer, it remains time- and resource-intensive to develop. Deep learning and generative AI models can rapidly identify novel targets, predict chemical interactions, and engineer stable drug candidates. Cuffari speaks with Sofia Michopoulou, PhD, a medical physics expert leading Nuclear Medicine Physics at University Hospital Southampton, who notes that AI-driven computer simulations can "identify the most promising pharmaceutical candidates earlier, reduce the current volume of preclinical work, and make early-phase evaluation more focused and efficient".
Personalized Dosimetry and Digital Twins
AI models also optimize dosimetry—the calculation of radiation absorbed by tissues to maximize tumor damage while sparing healthy organs. 3D convolutional neural networks analyze medical images to predict biodistribution, while machine learning can also generate patient-specific digital twins for advanced, individualized treatment planning, writes Cuffari.
Barriers to Clinical Adoption
Despite these advances, translation to the clinic is hindered by a lack of standardized, high-quality datasets to train AI models. While techniques like federated learning can protect patient confidentiality across hospital sites, extensive foundational experimental research is still required to ensure models generalize appropriately.
Please cite as:
Cuffari B. AI-Designed Radiopharmaceuticals: How Machine Learning Is Redefining Precision Cancer Therapy
J Med Internet Res 2026;28:e106201
URL: https://www.jmir.org/2026/1/e106201
doi: 10.2196/106201
About JMIR Publications News and Perspectives
JMIR Publications is a leading open access publisher of digital health research. The News and Perspectives section is the newest addition to its portfolio, established to bring the rigor and integrity of academic publishing to scientific journalism. The section features well-researched, expert-driven content from the Scientific News Editor, Kayleigh-Ann Clegg, PhD, and a network of specialist JMIR Publications Correspondents to keep the digital health community informed, inspired, and ahead of the curve.
About JMIR Publications
JMIR Publications is a leading open access publisher of digital health research and a champion of open science. With a focus on author advocacy and research amplification, JMIR Publications partners with researchers to advance their careers and maximize the impact of their work. As a technology organization with publishing at its core, we provide innovative tools and resources that go beyond traditional publishing, supporting researchers at every step of the dissemination process. Our portfolio features a range of peer-reviewed journals, including the renowned Journal of Medical Internet Research.
To find out more about JMIR Publications, visit jmirpublications.com or connect with them on Bluesky , X , LinkedIn , YouTube , Facebook , and Instagram .
Media Contact:
Dennis O’Brien, Vice President, Communications & Partnerships
JMIR Publications
communications@jmir.org
+1 416-583-2040
The content of this communication is licensed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/4.0/ ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, published by JMIR Publications, is properly cited.
Journal of Medical Internet Research
Commentary/editorial
People
AI-Designed Radiopharmaceuticals: How Machine Learning Is Redefining Precision Cancer Therapy
9-Jul-2026